AlgiPharma granted Orphan Drug designation by FDA

AlgiPharma was granted Orphan Drug designation by the FDA for its sodium alginate oligosaccharide, OligoG in the treatment of cystic fibrosis (CF).

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

 

February 24, 2016

AlgiPharma starts two new Phase 2b trials in Cystic Fibrosis

AlgiPharma has started preparations for two new clinical phase 2b trials in cystic fibrosis patients. The two studies are:

“A double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.”

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

“A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization with Burkholderia spp.”

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Philip D Rye, R&D Director; phil.rye@algipharma.com

February 2015

AlgiPharma awarded four year grant from Norwegian Research Council

AlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”. This study will focus on extended long term safety studies and formulation changes to further develop the AlgiPharma drug candidate OligoG for the treatment of cystic fibrosis.

For further information, please contact:
Arne Dessen, Chairman of Board; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

February 2015

Technology Strategy Board (Innovate UK) & Innovation Norway – New Funding Success

Building on the previous success with the AlgiFerm project, AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), FMC Biopolymer, and SINTEF have secured additional funding from the UK’s Technology Strategy Board (now Innovate UK) and Innovation Norway for further investigation on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. The study will focus on developing methods for scaling-up microbial fermentation production of OligoG at CPI.

The project, ALGIPRO, is an innovative collaborative effort between Norway and the UK. It will translate over 20 years of academic research into an industrial scale production process for alginates. The Centre for Process Innovation Ltd. (UK) is leading the scale-up based on development by SINTEF (Norway). AlgiPharma AS (Norway) will use the product as the Active Pharmaceutical Ingredient in its development of medicines for cystic fibrosis, COPD and chronic wounds. FMC Biopolymer (UK, Norway) will market the product in existing and new applications within the food and pharmaceutical markets. If successful ALGIPRO  will facilitate the introduction of novel medicinal products to the market that will ease patient suffering and potentially reduce healthcare costs. In addition it will be a new tool in fighting multi-drug resistant bacteria. The project is funded through a joint UK-Norwegian initiative between the Technology Strategy Board and Innovation Norway.

For further information, please contact:
Arne Dessen, Executive Chairman; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

November 2014

Technology Strategy Board & Innovation Norway – Algiferm Project Success

The collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has been successful in achieving the project milestones. The participating groups which include CPI, SINTEF and AlgiPharma, have successfully demonstrated the feasibility for industrial scale microbial fermentation production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. This is a significant step forward in AlgiPharma’s development of its alginate oligomer technology. These results will facilitate the introduction of novel medicinal products to fight infection and disease, reducing patient suffering and potentially reduce healthcare costs. The project was funded through a joint UK-Norwegian initiative between the Technology Strategy Board and Innovation Norway.

For further information, please contact:
Arne Dessen, Executive Chairman; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

January 2014

AlgiPharma awarded four year grant from Norwegian Research Council

AlgiPharma has been awarded a four year grant from the Norwegian Research Council for the project “Tailored OligoG in the treatment of chronic infectious biofilms”. This study involving an international consortium will investigate microbial sources of raw material for AlgiPharma’s alginate technology and determine optimal oligomer length associated with specific known OligoG antimicrobial properties.

For further information, please contact:
Arne Dessen, Chairman of Board; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

July 2013

Technology Strategy Board & Innovation Norway – New Funding Success 

A collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has secured funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for a feasibility study on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. The 9 month study will focus on developing methods for the pilot scale microbial fermentation production of OligoG at CPI, with support from our partners at SINTEF, who provide the essential expertise in laboratory scale fermentation of alginates.

The alginate oligomer fermentation project, ALGIFERM, translates 20 years of academic research into an industrial scale feasibility study. The Centre for Process Innovation Ltd.(UK) is leading the scale-up, whereas AlgiPharma AS (Norway) needs the final product as an Active Pharmaceutical Ingredient in its development of medicines for cystic fibrosis, COPD and chronic wounds, like diabetic foot ulcers. The biofilm disrupting and antibiotic potentiating technology that has been developed by AlgiPharma was recently published (Khan S., et al., Antimicrob Agents Chemother. 2012;56(10):5134-41). If the scale-up is successful it will facilitate the introduction of novel medicinal products to the market that will ease patient suffering and potentially reduce healthcare costs. In addition it will be a new tool in fighting multi-drug resistant bacteria. Both AlgiPharma and CPI will obtain help from SINTEF (Norway), in this innovative collaborative effort between Norwegian and English researchers.

The project is funded through a joint UK-Norwegian initiative between the Technology Strategy Board and Innovation Norway.

For further information, please contact:
Arne Dessen, Executive Chairman; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

April 2013

The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms

Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, Onsøyen E, Myrvold R, Hill KE, Thomas DW.
Biofouling. 2013 Apr;29(4):413-21. doi: 10.1080/08927014.2013.777954.

External link to Pubmed.gov

Abstract

The influence of a novel, safe antibiofilm therapy on the mechanical properties of Pseudomonas aeruginosa and Acinetobacter baumannii biofilms in vitro was characterized. A multiscale approach employing atomic force microscopy (AFM) and rheometry was used to quantify the mechanical disruption of the biofilms by a therapeutic polymer based on a low-molecular weight alginate oligosaccharide (OligoG). AFM demonstrated structural alterations in the biofilms exposed to OligoG, with significantly lower Young’s moduli than the untreated biofilms, (149 MPa vs 242 MPa; p < 0.05), a decreased resistance to hydrodynamic shear and an increased surface irregularity (Ra) in the untreated controls (35.2 nm ± 7.6 vs 12.1 nm ± 5.4; p < 0.05). Rheology demonstrated that increasing clinically relevant concentrations of OligoG (<10%) were associated with an increasing phase angle (δ) over a wide range of frequencies (0.1-10 Hz). These results highlight the utility of these techniques for the study of three-dimensional biofilms and for quantifying novel disruption therapies in vitro.

For further information, please contact:
Philip D. Rye R&D Director; phil.rye@algipharma.com

April 2013

AlgiPharma awarded secured 2.700.000 NOK for joint UK/Norwegian innovation project

In collaboration with leading experts in fermentation at the Centre for Process Innovation (CPI, Newcastle, UK), Algipharma has secured combined funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for pilot scale studies for production of its promising new alginate oligomer drug candidate. The funding also provides for continued support from SINTEF consolidating their key expertise in laboratory scale fermentation of alginates.

For further information, please contact:
Arne Dessen, Chairman of Board; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

February 2013

NANO2021 NFR Program: Norwegian Research Council Funds AlgiPharma Consortium 9.750.000 NOK for advanced wound healing applications

AlgiPharma is part of a multi-disciplinary consortium that has been awarded funding from the Research Council of Norway (NANO2021 programme). The Research project called NanoHeal, led by the Paper and Fibre Research Institute (PFI), includes a range of international partners (NTNU, Faculty of medicine, Cardiff University, Swansea University and Lund University) investigating bio-compatible cellulose nanostructures for advanced wound healing applications.

For further information, please contact:
Philip D. Rye R&D Director; phil.rye@algipharma.com

October 2012